Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

CNY News
cnynews.com > ixp > 498 > p > ny-men-hair-loss-concerns

Men In Their 20s In New York Search For Hair Loss Topics More Than Any Other Age Group

2+ week, 4+ day ago   (288+ words) Hair loss is on the minds of many men across New York State. Lordhair studied Google searches for more than 1,900 hair loss terms. They also looked at prescription claims for hair loss medicine in all 50 states. New York ranked 16th in…...

Forbes
forbes.com > sites > scotttravers > 07/28/2026 > why-do-some-people-have-a-widows-peak-hairline-an-evolutionary-biologist-explains

Why Do Some People Have A Widow’s Peak Hairline? An Evolutionary Biologist Explains

1+ mon, 2+ week ago   (523+ words) Most people’s hairlines run more or less straight across the forehead. In some people, the hair dips down in the middle to form a distinct V, often called the widow’s peak. It’s one of the few human traits that almost…...

AOL.com
aol.com > articles > women-hair-loss-overlooked-decades-182231000.html

Women With Hair Loss Have Been Overlooked for Decades, But New Treatments Are Finally Coming to Market - AOL

2+ mon, 2+ week ago   (570+ words) The hair loss drug pipeline has cracked open after three decades of stagnation, and this time women aren’t an afterthought. Three new treatments are in late-stage clinical trials right now, with real data behind them and timelines that could put…...

BioPharma APAC
biopharmaapac.com > news > 31 > 8032 > dayspring-pharmas-cg2001-meets-phase-ii-endpoint-in-male-androgenetic-alopecia-trial.html

Dayspring Pharma's CG2001 Meets Phase II Endpoint in Male Androgenetic Alopecia Trial

3+ mon, 4+ day ago   (180+ words) 09 June 2026 | Tuesday | News CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia. The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once…...

BIOENGINEER.ORG
bioengineer.org > human-telomerase-structures-unveil-bibr1532-inhibition-mechanism

Human Telomerase Structures Unveil BIBR1532 Inhibition Mechanism

3+ mon, 1+ week ago   (252+ words) Moreover, the identification of a structurally conserved allosteric pocket across species hints at the broader applicability of this inhibition mechanism. It opens avenues for exploring similar strategies in telomerases from other organisms, which could be relevant for diseases linked to…...

Google News
weeklyvoice.com > new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer – Weekly Voice

3+ mon, 3+ week ago   (87+ words) New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer Weekly Voice The Largest South Asian News Platforms since 1997 Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses…...

GlobeNewswire News Room
globenewswire.com > news-release > 05/17/2026 > 3296268 > 0 > en > new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer.html

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

3+ mon, 3+ week ago   (176+ words) May 17, 2026 15:30 ET | Source: Novartis Pharma AG Novartis Pharma AG Results show that patients treated with Pluvicto experienced a higher frequency and depth of PSA response when combined with SoC (androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to…...

NBR_magazine
nutraceuticalbusinessreview.com > martinbauer-nutraceuticals-launches-annurtricomplex-ingredient-for-hair-growth

MartinBauer Nutraceuticals launches AnnurTriComplex ingredient for hair growth and follicle health

3+ mon, 4+ week ago   (387+ words) The nutra brand has introduced AnnurTriComplex, a polyphenol-rich Annurca apple ingredient clinically studied for its potential to support hair growth, follicular activity, hair strength and density MartinBauer Nutraceuticals has announced the launch of its new ingredient AnnurTriComplex, designed to support…...

AOL.com
aol.com > articles > experimental-hair-loss-pill-just-100000111.html

Experimental hair loss pill just cleared a major hurdle — when it could hit shelves - AOL

4+ mon, 1+ week ago   (573+ words) It’s not something to brush off. Hair loss is a widespread problem in the US, with roughly 50 million men and 30 million women experiencing pattern baldness. No special potion completely reverses genetic or age-related decline, but there are a few products…...

New York Post
nypost.com > 05/05/2026 > health > experimental-hair-loss-pill-cleared-major-hurdle-when-it-could-hit-shelves

Experimental hair loss pill just cleared a major hurdle — when it could hit shelves

4+ mon, 1+ week ago   (715+ words) It’s not something to brush off. Hair loss is a widespread problem in the US, with roughly 50 million men and 30 million women experiencing pattern baldness. No special potion completely reverses genetic or age-related decline, but there are a few products…...